Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion
DNA
April 28 : AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic medicines. Here are some details: • Under the agreement, Profluent will use its artificial intelligence technology to create custom enzymes designed to make precise changes to DNA. • Lilly will have exclusive rights to further develop selected enzymes and bring any resulting medicines to market. CNA
din zilele anterioare